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By April 21, 2020, the official number of Covid-19 cases comprised of 2,397,217 confirmed cases and
162,956 fatalities worldwide (W. H. O., 2020). While waiting for a viable vaccine, the disease severity
continues to devastate the world population following a critical exponential trend. Open
perspectives on neutralizing the right antigenic structural protein of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) are broad. Several protein targets exist, including the
nucleocapsid, spike, envelope, membrane, and nine putative accessory factors of the virus. However,
so far, leading efforts in producing a vaccine mainly focus on the principal target of the humoral
immune response, the glycosylated SARS-CoV-2 spike trimer, that mediates cell entry and
membrane fusion. Although unusual, based on past experiences, highly respected researchers
now believe this approach may lead to the opposite intended effects and result in rapid initiation of a
macrophage activation syndrome (MAS) (Iwasaki and Yang, 2020). In the worst scenario, MAS
ultimately switches macrophages from a wound-healing beneficial behavior to a proinflammatory
phenotype, exacerbating the host. Patients with MAS overproduce proinflammatory molecules like
transferrin, IL-6, IL,8, and MCP1, and lose the critical tissue-repair cytokine TGFb. Together, this
would generate a worsening of the disease and, thus, be an immediate threat to life.
Just recently, efforts on an alternative promissory approach was approved. The principle is simple.
Recycling established pharmacological drugs and clinical molecules that might perturb the interactome of
SARS-CoV-2 patients diagnosed with Covid-19 could provide relief on their pathological status. So far, a
French research team has provided new but questionable (https://blogs.sciencemag.org/pipeline/archives/
2020/04/11/the-latest-hydroxychloroquine-data-as-of-april-11) conclusions by following an open-label
non-randomized clinical trial using a few individuals infected with Covid-19 and hydroxychloroquine
and azithromycin as a treatment (Gautret et al., 2020). A second-team tested the protein-protein
interactions between human embryonic kidney cells (HEK-293T) and SARS-CoV-2 infection,
uncovering several different drugs and compounds of potential clinical value (Gordon et al., 2020).
Furthermore, one more research group tested the FDA-approved drug Ivermectin on the SASRS-CoV-
2 replication inhibition using the African green monkey kidney VERO/hSLAM cells (Caly et al., 2020).
However, at this stage, the three approaches present severe constraints. Testing a broad panel of chemical
drugs directly on volunteer patients includes critical issues surrounding the patient’s physiological life,
treating risk, genetic differences, and the danger of strong ethical considerations. With this approach, while
recommendations exist to screen the compounds at early stages by using in vitro cell cultures, and HEK-
293T or VERO/hSLAM kidney cells are permissive to SARS-CoV-2 infection, they do not represent in any
way the primary physiological site of infection and fully overpass the knowledge that a full live organism
can provide in vivo.in.org May 2020 | Volume 11 | Article 6801
Galindo-Villegas The Zebrafish Disease Model Against Covid-19Animal models of human diseases have proven effective in the
screening of pharmacological drugs and in further determining the
specific therapeutic targets in humans. Therefore, a collection of
reliable animal models that replicates the Covid-19 clinical
symptoms is urgently needed in order to decipher the
transmission route and pathobiology of the disease. Among the
available model candidates, a wide selection exists with murine
models on top of the list (Callaway, 2020). However, a handy
vertebrate, the zebrafish, emerges as an outstanding and specific
poised model for the screening of novel therapeutics and chemical
modifiers of biological processes in vivo. The zebrafish is an
extremely versatile organism that, following proper automated
settings, can be visually inspected using transmitted light or
fluorescent imaging. At the same time, the signaling pathways,
chemical interactions, and physical forces that regulate the
development and progress of the host-virus interactions on
mucosal tissues are amenable to analysis with exquisite detail.
Indeed, the process of chemical throughput screening using the
full organism is simple. The early developmental stages behave in a
well-plate similarly to the cells used inmust laboratories practicing in
vitro testing approaches with pharmacological drugs. As a matter of
support, it is worth noting that no matter the physiological
differences, 84% of human genes associated with the specific
disease have a counterpart in zebrafish, and the crosstalk of viral
glycoproteins at the fish nasal neuro-immune edge are understood
(Sepahi et al., 2019). Therefore, reliable projections suggest that
employing zebrafish for analyses may provide faster, more accurate,
reliable, and holistic responses compared with single-cell entities.
Several human viruses colonize zebrafish, such as Sindbis,
chikungunya, and influenza A, as well as a variety of airborne
bacteria and fungi (Gomes and Mostowy, 2020). A variety of
mycobacteria affecting humans have been studied using this model
on a level 3 biosecurity facility. Tuberculosis pathogenesis is a sound
example, and the infection is established in zebrafish larvae using
Mycobacterium marinum (a close relative of Mycobacterium
tuberculosis), then screened in vivo by real-time fluorescent
microscopy and automated plate fluorometry (Takaki et al., 2013).Frontiers in Pharmacology | www.frontiersin.org 2Infection clearance was achieved following an in vivo screening of
large chemical libraries on 96-well microplates, with only 0.1 µmol of
drug per fish. Among the drugs recently proposed for use against
Covid-19 (Gordon et al., 2020), metformin (Met) has been suggested.
Potentially beneficial effects of Met on cellular metabolism, immune
function, and gene transcription involved in innate host responses to
Mycobacterium tuberculosis pathogenesis has been successfully
screened, linking the core of radially arranged microtubules at the
axoneme of variated human respiratory diseases with the zebrafish.
No matter how severe the impact of Covid-19 is, the
association of the incredible medical power in several
profoundly impacted nations possessing zebrafish facilities
working together with world-top scientists (like those at the
Boston Children Hospital in the USA, Karlsruhe Institut für
Technologie in Germany, Hospital for Sick Children in Canada,
Regenerative Medicine Institute in Australia, Western General
Hospital in the UK, or Hospital Universitario Virgen de la
Arrixaca in Spain) with cutting-edge technology and full
capacities in the use, the application of the above-described
zebrafish techniques could provide novel results soon.
We face a huge public health emergency (Song and Karako, 2020),
thus, the sole intention of this perspective is to urgently inspire the
medical community to explore the compound effect and associated
molecular mechanisms of the proposed pharmacological drugs on
this alternative approach committed toward fighting the pandemic.AUTHOR CONTRIBUTIONS
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